adenoma status and then identify CRCs post colonoscopy in the two groups, to make their findings interpretable for the scientific community.
4. The description of study methodology and results is long drawn out with many paragraphs devoted to just the linkage of records and sources of CRC identification. Most of this description belongs in a supplementary appendix. Every study goes through this process, nothing original is added to the literature on this account. Some of the basic linkage procedures are presented in very elementary tables starting with the universe of records at their hospital, the universe of cancer records at the cancer registry etc (it is irrelevant how many cases are documented in the registry). Examples are Table 2 , and the text in most of the Methods section.. They are best served by setting up a figure showing inclusion and exclusion criteria for selection of patients. The only information related to their study from the cancer registry side is that of 404 total CRC identified, about 10% of cancers were not found in either the local registry (ACT) or the larger NSW (I think they mean New South Wales, not explained in the paper) and these were sourced from hospital medical records. That is concerning because it raises the spectre of incomplete cancer case capture, indicating that their PCCRC rate of 0.435/1000 remains open to question.
5. The study significance and contribution to literature remains unclear. Many studies with much more systematic patient followup or rigorous cancer registries with very low case miss rates are already documented.
6. Most of the text can be reported in a brief report, as much description is (apologies to say it) mundane with no scientific relevance.
7. The writing style needs much improvement. Information is scattered through the paper and tables in haphazard fashion. As my above comments bear out, it is imperative that for a start, the authors should carefully review professionally written papers on their topic and use those as a model to present their work. It is difficult for me to know where to begin in providing specific comments because of a lack of professional writing through most of the paper.
REVIEWER
Amitabh Srivastava Brigham and Women's Hospital, Boston, MA (USA) REVIEW RETURNED 26-Dec-2018
GENERAL COMMENTS
The authors report on the incidence of post colonoscopy cancers within a defined geographic area in Australia. This is a nice study and an obvious strength of the study is the population-based setting but several limitations must be addressed: 1. The authors correctly state that the definitions of post colonoscopy cancers used in various studies is variable. However, a cancer diagnosis within 6-12 months of an index colonoscopy may represent either a missed cancer or a scenario where no biopsies were performed because of an obvious malignant diagnosis and the patient was referred directly to surgery. Including the latter cases in post colonoscopy cancer group will be misleading and overestimate the proportion of post colonoscopy cancers. If the authors wish to include cancers diagnosed within 12 months (which is different from most prior studies), they must elaborate on the findings reported in index colonoscopy in these patients. Otherwise, cancers diagnosed within 12 months of an index colonoscopy should be excluded from the PCCRC group. 2. Similarly, including patients with a hereditary predisposition to colorectal cancer such as Lynch syndrome or FAP and those with inflammatory bowel disease along with average risk screening/surveillance colonoscopies is misleading. The IBD, FAP and Lynch patients should be excluded from the PCCRC group since we know these are high risk patients and undergo intensive surveillance with colonoscopies every 1-2 years anyway and cancers detected on follow up are usually early stage which is a very different scenario from the usual post colonoscopy cancers. 3. Routine screening for colorectal cancer is usually recommended after the age of 50 but nearly 40% of patients included in the study were less than 50 years old. This is likely due to inclusion of inflammatory bowel disease patients and those with high familial risk for colorectal cancer. It is well established that the risk of cancer in these latter groups is much higher than the general population and the issue of post colonoscopy cancers is more relevant to patients who are average risk. The authors must address this issue comprehensively since this will have a great impact on the study findings and its conclusions. 4. The indication for colonoscopy in nearly 25% of patients with a post colonoscopy cancer is mentioned as follow-up of polyps/cancer. It seems that these are better categorized as surveillance detected carcinomas and it is unclear why they were included in this group. The purpose of colonoscopy is not only to prevent development of carcinoma but also to detect carcinomas at early stage in order to reduce mortality from colorectal cancer. Patients with adenomas or serrated polyps may develop new cancers that may be detected on a surveillance examination but are usually early stage. In most studies, only diagnostic examinations are included within post colonoscopy cancers. The authors must exclude these cases from the post colonoscopy group or provide a rationale for why they chose to include them here. Similarly, there is one post colonoscopy cancer patient where the indication is listed as "family history" and should be excluded because of issues #2 and 3 discussed above. It might also explain why the authors did not find the right colon dominance in PCCRC reported in almost all prior studies on the subject. 5. Since the authors seem to have access to pathology data it would add significantly to the strength of the study if they could comment on presence of prior conventional adenomas and/or serrated polyps in the PCCRC and non-PCCRC groups? This can be added to 
VERSION 1 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
The authors sought to determine post colonoscopy CRC rates in a cohort of colonoscopy patients served by a hospital system. The study has a number of methodological and presentation issues that are summarized below:
Major comments:
1. The study objective is unclear as is the meaning and interpretation of findings for the state of art of colonoscopy outcomes. The objective section in the abstract states they want to address the fact that post colonoscopy colorectal cancers are a critical indicator. The text itself does not mention the study objective either at the close of the Introduction section or in the Methods section.
We thank the Reviewer but disagree with this point. The close of the Introduction section states:
'The aim of this study was to accurately determine the PCCRC incidence in our geographically small but populous Australian jurisdiction, by exploiting the availability of three separate database sourcesa prospective colonoscopy database, a hospital records system, and a regional cancer registry. We sought to maximise one-to-one linkage, and enable benchmarking in our jurisdiction and other regional jurisdictions.'
2. The authors should take a stand by describing in the text what proportion had normal findings, adenoma, and IBD. Diverticulosis and haemorrhoids are incidental to the PCCRC outcome. Table 1 is the only source to guess this information. It presents the distribution of patients by bowel status that does not add up to 100%.
We thank the Reviewer for raising this point. It is expected that the % frequency of findings at colonoscopy in Table 1 do not add up to 100%, as patients may have more than one finding at colonoscopy. Table 1 shows that 39.5% of patients had normal colonoscopies. Of the remaining patients, there are different combinations of between one to four abnormalities. This yields 15 possible different combinations of findings. We did not tabulate these combinations.
We believe the reviewer is incorrect with respect to diverticulosis. Diverticulosis is not incidental to the PCCRC outcome, but is a predictor of PCCRC as shown by a finding of our study and by others, as presented in the abstract, in the results text, in Table 3 , and in the Discussion.
PCCRC has been applied to post screening colonoscopies whether done as the primary screening test or secondary test following abnormal primary test finding (such as positive faecal test). This study is best served by excluding the 7.4% with bowel pathology patients to make it comparable to other studies of PCCRC.
We thank the Reviewer, but we think this is incorrect in terms of the definition of PCCRC and in terms of other studies. PCCRC is defined by the World Endoscopy Organisation as 'the preferred term for cancers appearing after any colonoscopy in which no cancer is diagnosed'. Since our submission to BMJ Open, this definition has been published 19. We have amended the manuscript to further address the consensus statements.
3. The authors state that their rate of 0.435 is comparable to the National Polyp Study which had a 0.59 rate which is not tenable.
We thank the Reviewer for these points. We have deleted the sentence, however we point out that we stated (page 20): "However our study incidence rate was similar to the National Polyp Study where the rate of cancer during follow-up colonoscopy was 0.6/1000 person years of observation."
This sentence follows a paragraph referring to other studies that report incidence rates, all somewhat higher. Studies reporting incidence are cohort studies and unlike our study they describe specific patient cohorts. As a result, as we stated in this paragraph:
"The higher incidence rate of PCCRC in the above studies may be attributed to including patients with a higher risk such as subjects with a history of adenoma."
The NPS cohort consisted of patients without bowel pathology, 100% consisting of patients found with adenomas at screening and followed up after colonoscopy. Adenoma patients have multifold higher risk of interval cancer than no-adenoma patients. By this measure, this study's rate of PCCRC is about 3-fold higher than the NPS, because the study cohort has 33.5% adenoma patients, the remaining are no-adenoma patients.
We respectfully disagree with the Reviewer regarding the baseline assumptions and methodology of this analysis. Persons with a personal history of adenoma are at higher lifetime risk of CRC, but as to PCCRC, a large study published since our submission reported that patients with a finding of adenoma without advanced histology had an OR of 1.87 (c.i. 1.37 -2.55) of PCCRC within the next ten years (not five years), compared to patients with no adenoma, in univariate analysis (Tollivoro TA et al. Gastrointest Endosc. 2019; 89(1):168-176) . In contrast, the OR for PCCRC within 5 years in those with diverticulosis was 3.62 in our study (c.i. 1.39 -9.39), and similar in the other studies we cite. In addition, our study controlled for exposure, so patients with adenoma would be expected to be scheduled for follow-up examination within 3-5 years, although not patients with diverticulosis.
. The authors should limit the study to average risk persons who had the colonoscopies (i.e. exclude bowel pathology patients), classify by adenoma status and then identify CRCs post colonoscopy in the two groups, to make their findings interpretable for the scientific community.
We thank the Reviewer but disagree with these points for the reasons above.
4. The description of study methodology and results is long drawn out with many paragraphs devoted to just the linkage of records and sources of CRC identification. Most of this description belongs in a supplementary appendix. Every study goes through this process, nothing original is added to the literature on this account. Some of the basic linkage procedures are presented in very elementary tables starting with the universe of records at their hospital, the universe of cancer records at the cancer registry etc. (it is irrelevant how many cases are documented in the registry). Examples are Table 2 , and the text in most of the Methods section. They are best served by setting up a figure showing inclusion and exclusion criteria for selection of patients.
We thank the Reviewer but disagree, as the probabilistic (machine learning) linkage methodology we report is novel to this submission. With respect to description of the linkage, Table 2 describes the data sources for the study and Figure 1 is a schematic of the results of linkage. We believe both are necessary for an understanding of the data or reproduction of the methodology. Only 104 words of text are used to describe the results of data linkage.
The only information related to their study from the cancer registry side is that of 404 total CRC identified, about 10% of cancers were not found in either the local registry (ACT) or the larger NSW (I think they mean New South Wales, not explained in the paper).
We disagree with the reviewer as to the abbreviation. NSW is written out as 'New South Wales (NSW)' in its first occurrence in the abstract of our submission as follows:
"We performed a cohort study of individuals who underwent colonoscopy between 2001 and 2008 at a single centre serving Australian Capital Territory (ACT) and enclaving New South Wales (NSW) region."
NSW is then written out as 'New South Wales (NSW)' in its first occurrence in the body of our submission, in the Methods, as follows:
"We then identified individuals from this cohort subsequently diagnosed with CRC anywhere in ACT or New South Wales (NSW)."
..and these were sourced from hospital medical records. That is concerning because it raises the spectre of incomplete cancer case capture, indicating that their PCCRC rate of 0.435/1000 remains open to question.
We thank the Reviewer but we disagree on this point. There are several causes of linkage failure, which we report in our Results section under the heading 'Reasons for linkage failure.' Linkage failure only becomes apparent if a complementary linkage method is used, and this is a methodological strength of our submission -not a weakness.
5. The study significance and contribution to literature remains unclear. Many studies with much more systematic patient follow-up or rigorous cancer registries with very low case miss rates are already documented.
We thank the Reviewer but we disagree on this point. We show relevant comparator studies in Table  5 . The terms 'systematic' and 'rigorous' are arbitrary, and the term 'low case miss rates' is inherently false. Even in the National Polyp Study3, a controlled trial, 39 (3%) participants were lost to follow up, and only 5 PCCRC were ascertained. The majority of studies are retrospective studies based on linkage of cancer registrations to one or more databases showing prior colonoscopy. The 'case miss rates' in these studies are the sum of missed registrations for each linked database and linkage failure, and are unknown and unreported.
With respect to Cancer Registries in different countries reporting PCCRC, there are no data regarding comparative completeness of cancer registries. We report in our submission that timeliness (lag to registration and publication) was a potential weakness of our study.
We do note, in a general sense, that Australian Cancer Registries are well regarded. Harmonisation of the State Cancer Registries was undertaken in conjunction with the Australian Institute of Health and Welfare in 1982, ten years before this process was undertaken in the United States (SEER).
We thank the Reviewer but we disagree on this point for the reasons above.
We thank the Reviewer but we partly disagree on this point. We have significantly revised the manuscript since review to aid readability. Respectfully we disagree that the Reviewer's above comments bear out the Reviewer's impression, as we believe some of them are incorrect.
Reviewer: 2
The authors report on the incidence of post colonoscopy cancers within a defined geographic area in Australia. This is a nice study and an obvious strength of the study is the population-based setting but several limitations must be addressed:
1. The authors correctly state that the definitions of post colonoscopy cancers used in various studies is variable. However, a cancer diagnosis within 6-12 months of an index colonoscopy may represent either a missed cancer or a scenario where no biopsies were performed because of an obvious malignant diagnosis and the patient was referred directly to surgery. Including the latter cases in post colonoscopy cancer group will be misleading and overestimate the proportion of post colonoscopy cancers. If the authors wish to include cancers diagnosed within 12 months (which is different from most prior studies), they must elaborate on the findings reported in index colonoscopy in these patients. Otherwise, cancers diagnosed within 12 months of an index colonoscopy should be excluded from the PCCRC group.
We thank the Reviewer and agree with these points. We propose to utilise the recent definition of PCCRC19, which encompasses all 15 cases of PCCRC in our cohort. As suggested by the Reviewer, we have amended the text, by providing findings at index colonoscopy in the 15 PCCRC patients (Supplementary table 2) , and pointing to this table in our Results section. No PCCRC case was a previously ascertained. However, the recent consensus statement allows for the diagnosis of PCCRC up to ten years after a colonoscopy negative for cancer. As this definition was not in place at the time of our study, we have noted this in the text as follows:
• Results, p16: In 7 cases the diagnosis of CRC was made more than 5 years but less than ten years after the previous index colonoscopy19.
• Discussion, p20: A recent consensus statement holds that PCCRC is the preferred term for cancers appearing after a colonoscopy in which no cancer is diagnosed.19 As a quality assurance term, PCCRC refers to CRC detected after any such complete prior colonoscopy. The term 'interval cancer' was recommended for CRC (or other cancer) arising before the next recommended screening or surveillance procedure.
2. Similarly, including patients with a hereditary predisposition to colorectal cancer such as Lynch syndrome or FAP and those with inflammatory bowel disease along with average risk screening/surveillance colonoscopies is misleading. The IBD, FAP and Lynch patients should be excluded from the PCCRC group since we know these are high risk patients and undergo intensive surveillance with colonoscopies every 1-2 years anyway and cancers detected on follow up are usually early stage which is a very different scenario from the usual post colonoscopy cancers.
We thank the Reviewer and agree in part with these points. The term PCCRC is now clearly defined as including all cases, whether diagnostic or screening, and with different risk profiles. Familial cancers can be included in PCCRC according to the recent expert statement, although with a recommendation that these details be recorded (Statement 7). We have recorded a Lynch diagnosis for 2 of our PCCRC cases. Only 4 of the index colonoscopies recorded a possible, unconfirmed Lynch diagnosis and these cases did not result in a PCCRC. We note that exposure in our KM analysis was calculated on the basis of time to the next colonoscopy. Therefore, our results are controlled for exposure.
3. Routine screening for colorectal cancer is usually recommended after the age of 50 but nearly 40% of patients included in the study were less than 50 years old. This is likely due to inclusion of inflammatory bowel disease patients and those with high familial risk for colorectal cancer. It is well established that the risk of cancer in these latter groups is much higher than the general population and the issue of post colonoscopy cancers is more relevant to patients who are average risk. The authors must address this issue comprehensively since this will have a great impact on the study findings and its conclusions.
We thank the Reviewer and agree with these points, which we have addressed in our response to point 1.
4. The indication for colonoscopy in nearly 25% of patients with a post colonoscopy cancer is mentioned as follow-up of polyps/cancer. It seems that these are better categorized as surveillance detected carcinomas and it is unclear why they were included in this group. The purpose of colonoscopy is not only to prevent development of carcinoma but also to detect carcinomas at early stage in order to reduce mortality from colorectal cancer. Patients with adenomas or serrated polyps may develop new cancers that may be detected on a surveillance examination but are usually early stage. In most studies, only diagnostic examinations are included within post colonoscopy cancers. The authors must exclude these cases from the post colonoscopy group or provide a rationale for why they chose to include them here. Similarly, there is one post colonoscopy cancer patient where the indication is listed as "family history" and should be excluded because of issues #2 and 3 discussed above. It might also explain why the authors did not find the right colon dominance in PCCRC reported in almost all prior studies on the subject.
We thank the Reviewer and agree in part with these points. We refer to our response to point 1 in relation to the inclusion criteria for the cohort. The majority of patients with prior cancer would have been excluded on the basis of a post-surgical colon, with the exception being those with anterior resection only.
5. Since the authors seem to have access to pathology data it would add significantly to the strength of the study if they could comment on presence of prior conventional adenomas and/or serrated polyps in the PCCRC and non-PCCRC groups? This can be added to Table 4 in separate rows (any conventional adenoma, advanced adenoma, multiple adenomas, any serrated polyps, large serrated polyps, both advanced adenomas and large serrated polyps). This is important because it has been recently shown that patients with both high-risk adenomas and large serrated polyps represent a high risk group (Anderson J et al Gastroenterology 2018) . Was the prevalence similar or were serrated polyps (particularly SSP type lesions) more likely to be seen in the PCCRC compared to non-PCCRC groups?
We agree with the Reviewer. Although we described our data sources, which did not include a pathology database, we did not explicitly state that we did not have pathology data for the cohort. For all CRC diagnosed (incident CRC and PCCRC), pathology data from index colonoscopies was derived by manual lookup. This has now been specifically noted in the section 'Data collection.' 5. Also, in patients who did have a prior history of a polypectomy were the PCCRC diagnosed in the same region? If yes, this would indicate an incompletely excised precursor as a likely cause of the PCCRC.
We thank the Reviewer and agree. We have amended the Results as follows:
'Of our 15 PCCRC, 7 were detected in individuals who had prior polypectomy; in two of these cases a polyp was removed in the same region of the colon.'
We also note this is our Discussion but do not take the observation any further.
6. The indications for the index colonoscopies should be elaborated further as screening, surveillance or diagnostic.
We thank the Reviewer and agree. The indications have now been specifically noted as screening, surveillance or diagnostic in Table 4. 7. The authors mention in the study design that the Canberra Hospital performs 60% of the public colonoscopies in the ACT. Is the demographic and ethnic distribution of the population and the skill of gastroenterologists covered by this hospital similar to the remaining 40% of the population? If yes, the findings may be generalized to the entire population but if colonoscopies are being done by family practitioners and surgeons and less skilled GI docs in the remaining 40%, then the findings reported here may be an underestimate of the incidence of PCCRC in the entire population. This must be briefly addressed in the discussion.
We thank the Reviewer and agree. We have corrected the text by replacing the ambiguous term 'public colonoscopies' with 'publicly funded colonoscopies' in the Methods (Study Design) section and Discussion. We have no data comparing our patient population with the overall regional population.
We have elaborated where possible on the comparability of the ACT and Australian population. The Discussion now reads: 'Our institution performs the majority of publicly funded colonoscopies performed in the region. We have no data comparing our patient population with the overall regional population. The ACT population is comparable to the broader Australian population, but to a significant degree is more affluent and more likely to hold tertiary education qualifications, and is somewhat less linguistically and culturally diverse43. With these caveats, we believe our results to broadly reflect the Australian population.
One factor distinguishing our facility from other local facilities was that trainees completed 34% of index colonoscopies in the cohort. There was a non-significant trend for these cases to be associated with PCCRC.'
8. The authors report tumour IHC, MSI and BRAF mutation findings under the results but discussion about these findings is lacking. There is recent data not just on MSI but also the genetic landscape of post colonoscopy cancers using NGS that suggests that most PCCRC cases include missed or incompletely excised precursors (Soong TR et al Modern Pathology 2018). The manuscript would benefit from a brief discussion about implications of IHC and molecular findings reported in post colonoscopy cancers in this and prior studies.
We thank the Reviewer and agree that our discussion did not compare PCCRC and incident CRC in detail. Our focus in this paper was on optimisation of PCCRC detection in the cohort. This means that we did not detect other PCCRC (CRC occurring during the period with an index colonoscopy performed elsewhere). These CRC were excluded from the cohort, but we did make comparisons between PCCRC and incident CRC (summarised in Table 4 ). We have now noted this point in the Discussion as follows:
"We note that our study design optimizes detection of PCCRC arising in our cohort. We did not detect all PCCRC occurring during the period. Some CRC diagnosed during the period of this study may have been PCCRC if an index colonoscopy had been performed elsewhere within the previous ten years. All these cases were excluded from our cohort but were used as a comparator group for analysis of factors associated with PCCRC. The degree to which this influences our comparisons was not ascertained." In relation to the substantive point raised by the Reviewer, we have added to the Discussion a brief analysis of the literature pertaining to MMR and other biological alterations PCCRC compared to incident CRC. This section of the Discussion now reads: "The reported higher frequency of right-sided PCCRC may arise from these CRC being more biologically aggressive, or alternatively from right-sided precursor lesions being more likely to be undetected or incompletely removed at prior examinations. The former explanation is supported by the observation of a higher frequency of abnormal MMR expression in PCCRC41. However, recently Soong and colleagues performed analysis of cancer gene mutations and copy number variation by targeted exon capture and deep sequencing in interval CRC detected at a single institution42. When interval CRC were compared to incident CRC matched to age, gender and tumour location, there were no appreciable differences in any classifying molecular alteration in interval CRCs, pointing to a similar biological behaviour of interval and incident CRC. Soong et al. concluded that interval PCCRC were therefore likely to result from missed or recurrent lesions. We did not find a significant difference in abnormal expression of MMR proteins between PCCRC and incident cancers. We found 2 of 15 PCCRC were detected in individuals who had prior polypectomy in the same region of the colon." 
GENERAL COMMENTS
My concerns have been adequately addressed by the authors. I would recommend acceptance of the manuscript
